<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>OBJECTIVE: To estimate the health utility scores associated with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp>, its treatments, complications, and comorbidities </plain></SENT>
<SENT sid="1" pm="."><plain>RESEARCH DESIGN AND METHODS: We analyzed health-related quality-of-life data, collected at baseline during Translating Research Into Action for <z:mp ids='MP_0002055'>Diabetes</z:mp>, a multicenter, prospective, observational study of <z:mp ids='MP_0002055'>diabetes</z:mp> care in managed care, for 7,327 individuals with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="2" pm="."><plain>We measured quality-of-life using the EuroQol (EQ)-5D, a standardized instrument for which 1.00 indicates perfect health </plain></SENT>
<SENT sid="3" pm="."><plain>We used multivariable regression to estimate the independent impact of demographic characteristics, <z:mp ids='MP_0002055'>diabetes</z:mp> treatments, complications, and comorbidities on health-related quality-of-life </plain></SENT>
<SENT sid="4" pm="."><plain>RESULTS: The mean EQ-5D-derived health utility score for those individuals with <z:mp ids='MP_0002055'>diabetes</z:mp> was 0.80 </plain></SENT>
<SENT sid="5" pm="."><plain>The modeled utility score for a nonobese, non-insulin-treated, non-Asian, non-Hispanic man with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp>, with an annual household income of more than $40,000, and with no <z:mp ids='MP_0002055'>diabetes</z:mp> complications, risk factors for <z:e sem="disease" ids="C0007222" disease_type="Disease or Syndrome" abbrv="CVD">cardiovascular disease</z:e>, or comorbidities, was 0.92 </plain></SENT>
<SENT sid="6" pm="."><plain>Being a woman, being <z:mp ids='MP_0001261'>obese</z:mp>, smoking, and having a lower household income were associated with lower utility scores </plain></SENT>
<SENT sid="7" pm="."><plain>Arranging complications from least to most severe according to the reduction in health utility scores resulted in the following order: <z:hpo ids='HP_0004950'>peripheral vascular disease</z:hpo>, <z:e sem="disease" ids="C0178273" disease_type="Disease or Syndrome" abbrv="">other heart diseases</z:e>, <z:hpo ids='HP_0002326'>transient ischemic attack</z:hpo>, <z:e sem="disease" ids="C0038454" disease_type="Disease or Syndrome" abbrv="">cerebral vascular accident</z:e>, nonpainful <z:e sem="disease" ids="C0011882" disease_type="Disease or Syndrome" abbrv="">diabetic neuropathy</z:e>, <z:hpo ids='HP_0001635'>congestive heart failure</z:hpo>, dialysis, <z:hpo ids='HP_0002301'>hemiplegia</z:hpo>, painful <z:e sem="disease" ids="C0442874" disease_type="Disease or Syndrome" abbrv="">neuropathy</z:e>, and <z:mpath ids='MPATH_686'>amputation</z:mpath> </plain></SENT>
<SENT sid="8" pm="."><plain>CONCLUSIONS: Major <z:mp ids='MP_0002055'>diabetes</z:mp> complications and comorbidities are associated with decreased health-related quality-of-life </plain></SENT>
<SENT sid="9" pm="."><plain>Utility estimates from our study can be used to assess the impact of <z:mp ids='MP_0002055'>diabetes</z:mp> on quality-of-life and conduct cost-utility analyses </plain></SENT>
</text></document>